The new bond is the first of its kind in the healthcare industry and the first SLB incorporating social targets. The SLB represents another step in the company’s journey to further embed ESG into the core of its business operations and to communicate progress in a consistent and transparent way.
Novartis recently set new ambitious targets to increase patient reach in low- and middle-income countries by 2025. In addition, Novartis further strengthened its carbon neutrality target to aim for full carbon neutrality across its supply chain (Scope 1, 2, 3) by 2030. Read More
Novartis US Foundation to help improve health equity
The Novartis US Foundation announced a total commitment of USD 25 million to develop partnerships and fund community organizations and programs that address health inequities, with a focus on diversity in clinical trials, in the United States. This commitment reinforces the foundation’s mission to improve health in underserved communities in the United States by creating innovative and sustainable solutions to expand access to healthcare and build trust within the healthcare system. Read More